

Tavalisse™ (fostamatinib disodium hexahydrate) (Oral)

Document Number: IC-0361

Last Review Date: 02/04/2020

Date of Origin: 06/01/2018

Dates Reviewed: 06/2018, 02/2019, 02/2020

I. Length of Authorization

Coverage is provided for six months and may be renewed.

II. Dosing Limits

A. Quantity Limit (max daily dose) [Pharmacy Benefit]:

- 100 mg tablets – 2 tablets per day
- 150 mg tablets – 2 tablets per day

B. Max Units (per dose and over time) [Medical Benefit]:

- 300 mg daily

III. Initial Approval Criteria^{1,2,3,4}

Coverage is provided in the following conditions:

Universal Criteria

- Patient is not receiving a thrombopoietin receptor agonist or mimetic (e.g., romiplostim, eltrombopag, avatrombopag, etc.); **AND**
- Laboratory values are current (i.e., drawn within the previous 28 days); **AND**
- Fostamatinib disodium hexahydrate is not being used to attempt to normalize platelet count; **AND**

Chronic Immune Thrombocytopenia (ITP) †

- Patient aged 18 years or older; **AND**
- Patient has had persistent/chronic ITP for at least 3 months; **AND**
- Patient has previously failed any of the following treatments for ITP:
 - Patient has failed previous therapy with corticosteroids (i.e., patient had no response to at least a 3-month trial or is corticosteroid-dependent); **OR**
 - Patient has failed previous therapy with immunoglobulins; **OR**
 - Patient has had a splenectomy; **OR**

- Patient has failed previous therapy with a thrombopoietin receptor agonist; **AND**
- The patient is at increased risk for bleeding as indicated by platelet count of less than $30 \times 10^9/L$ ($30,000/mm^3$)

† FDA Approved Indication(s)

IV. Renewal Criteria¹

Coverage can be renewed based upon the following criteria:

- Patient continues to meet universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: hepatotoxicity (abnormal liver enzymes), hypertension, severe diarrhea and severe neutropenia, etc.; **AND**
- Disease response indicated by the achievement and maintenance of a platelet count of at least $50 \times 10^9/L$ as necessary to reduce the risk of bleeding and/or the patient has demonstrated a documented decrease in requiring rescue treatment with platelet transfusions.

V. Dosage/Administration

Indication	Dose
Chronic ITP	<ul style="list-style-type: none"> • Initiate at a dose of 100 mg, orally, twice daily. • After 4 weeks, if platelet count has not increased to at least $50 \times 10^9/L$, increase dose to 150 mg twice daily.

VI. Billing Code/Availability Information

HCPCS:

J8499- Prescription drug, oral, non-chemotherapeutic, Not Otherwise Specified

C9399 – Unclassified drugs or biologicals (*Hospital Outpatient Use ONLY*)

NDC:

- 100 mg tablets: 71332-0001-xx
- 150 mg tablets: 71332-0002-xx

VII. References

1. Tavalisse [package insert]. San Francisco, CA; Rigel Pharmaceuticals; April 2018. Accessed January 2020.
2. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. *Blood Adv.* 2019 Dec 10;3(23):3829-3866.

TAVALISSE™ (fostamatinib disodium hexahydrate) Prior Auth Criteria

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2020, Magellan Rx Management

3. Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. *Blood*. 2017. 129:2829-2835. doi:10.1182/blood-2017-03-754119.
4. Bussel J, Arnold DM, Grossbard E, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. *Am J Hematol*. 2018. doi: 10.1002/ajh.25125.

Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
D69.3	Immune thrombocytopenic purpura

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: <http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA, LLC
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA, LLC
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC